Kairos Pharma highlights 17.7-month progression-free survival with ENV-105 combination in metastatic prostate cancer
Kairos Pharma has presented interim Phase 2 findings showing substantially longer progression-free survival with ENV-105 plus apalutamide than with apalutamide alone. However, the number of patients in the analysis and key statistical details remain undisclosed, while a redesigned trial will test the treatment earlier in the course of resistance.